Irish diagnostics company creates employment to contribute further to the pharma industry.
Diaceutics is announcing 30 new jobs in the area of data analysis, global operations and marketing on the back of 60pc revenue growth.
The Irish diagnostics and data company works with 26 out of the world’s top 30 pharmaceutical companies and provides oversight of testing in 23 markets.
‘Some 70pc of new cancer drug launches will be diagnostics-dependent in the next five years’
– PETER KEELING
The jobs, which will be filled by the end of 2018, will facilitate further international growth for Diaceutics and allow it to expand its presence in all of its key markets including the US, Europe, Asia and South America.
The new roles will increase its global team to 100, and will be created at its headquarters in Ireland, its US headquarters in Parsippany, New Jersey, as well as in satellite offices in Asia and South America.
The future of pharmaceuticals is in analytics-driven testing
“Testing is now at the heart of pharmaceutical companies’ ability to identify the right patients for their new therapies,” said Diaceutics CEO Peter Keeling.
“We are uniquely positioned to provide the global testing perspective that allows this identification and treatment of patients who will benefit from specific and often life-saving drugs.
“To put the importance of what we do into context, we have put structures in place that, each year, help 48,000 cancer patients in the US and EU get biomarker testing and therefore, potentially gain access to the right drug for their specific condition,” Keeling explained.
Diaceutics forecasts that the precision medicine market in which it operates will grow from €1.4bn today to €4bn by 2020.
The company has been involved in more than 200 drug launches and currently has a 60pc share in the top 10 global markets.
Diaceutics recently strengthened its senior management team with the addition of three domain experts. Dr Juliesta E Sylvester is the new managing director of data and analytics, Dr Peter Krein is the new managing director of client operations, and Dr Merdol Ibrahim will lead the global laboratory implementation team.
“Some 70pc of new cancer drug launches will be diagnostics-dependent in the next five years,” Keeling said.
“Pharma will be relying on us to show them how they can maximise their market share in what is going to become an increasingly profitable area – and a hugely beneficial one to patients.”